{'fraction_non_alphanumeric': 0.025339366515837104, 'fraction_numerical': 0.008144796380090498, 'mean_word_length': 5.35632183908046, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparative study of mezlocillin and ticarcillin in the treatment of urinary tract infections.

Mezlocillin (1.5 gm) or ticarcillin (2 gm) was administered intramuscularly every six hours for seven days in this prospective, randomized study of 60 men with complicated urinary tract infections. The two patient groups were comparable as to age, weight, and infecting microorganisms. The underlying urologic disorders, which were comparable in the two groups, included hypertrophy of the prostate, carcinoma of the prostate, bladder tumors, and urethral strictures. No patient had an indwelling catheter for more than three days. Both drugs were well tolerated except for mild pain on injection. A cure of the urinary tract infection, defined as a negative urine culture one week after treatment, was obtained in 64% of the mezlocillin group and in 47% of the ticarcillin group. There was no statistical difference between these results. This study demonstrated that mezlocillin and ticarcillin, administered intramuscularly, were safe and effective in the treatment of complicated urinary tract infections.